Clinicians typically classify meningiomas—the most common type of brain tumor—into three grades, ranging from slow-growing to aggressive. But a new multi-institutional study suggests that appearances may be deceiving. If a tumor shows activity in a gene called telomerase reverse transcriptase, it tends to recur more quickly, even if it looks low-grade under the microscope.
Natural killer cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research from the University of Texas MD Anderson Cancer Center.
A new class of drug results in cancer cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint known as the G1/S checkpoint, according to research gathered by the Oser Lab at Dana-Farber Cancer Institute.
The most common cancer-causing strain of human papillomavirus, HPV16, undermines the body’s defenses by reprogramming immune cells surrounding the tumor, according to a preclinical study from researchers at the Keck School of Medicine of USC. In mice, blocking this process boosted the ability of experimental treatments for HPV to eliminate cancer cells.
Hua Wang, an assistant professor in the departments of Material Science & Engineering, Bioengineering, Materials Research Lab, and Biomedical and Translational Sciences, finetunes an important technology in biomaterial chemistry at the Cancer Center at Illinois, which could potentially make way for more potent cancer immunotherapies.
Acquired mutations in blood stem cells—whether arising from smoking, exposure to toxins or even normal aging—interact with mutations passed down by parents in important ways that influence a person’s lifetime risk of developing blood cancer, a study led by researchers at WashU Medicine found.
Some survivors of childhood cancer are more at risk for serious health issues as they grow older, including new cancers and chronic conditions like heart disease, according to a study published in the Journal of Clinical Oncology.
The MammaPrint, a gene expression profiling test, predicts the benefit of chemotherapy for patients with hormone receptor-positive, HER2-negative early-stage breast cancer, according to findings published in JNCI Cancer Spectrum.
ELI-002 2P, an off-the-shelf cancer vaccine, can trigger powerful and lasting immune responses, and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations, according to a study published in Nature Medicine.
KU Cancer Center has launched an investigator-initiated trial designed to attack three different targets on cancer cells at once. “The Triple Threat” approach is designed to boost CAR T-cell therapy’s chances of destroying blood cancers.
